1-8 of 8
Safiyyah Ziyad
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Trial in progress: QUINTESSENTIAL—a phase 2 study of arlocabtagene autoleucel (arlo-cel) in patients with relapsed/refractory multiple myeloma (RRMM)

Free
Ciara Louise Freeman, Sarah Larson, Omar Nadeem, Nikhil Munshi, Shinsuke Iida, Sham Mailankody, Paola Neri, Tara Gregory, Julia Piasecki, Safiyyah Ziyad, Hongxiang Hu, Svenja Johanna Groeneveld, Sarah Johnston, Timothy Pulham, Sandy Wong, Jaclyn Davis, Susan Bal, Anupama Kumar, Krina Patel
Journal: Blood
Blood (2025) 146 (Supplement 1): 4079.
https://doi.org/10.1182/blood-2025-4079
Published: 2025
Journal Articles

Trial in progress: A phase 1 study to evaluate the safety and preliminary efficacy of arlocabtagene autoleucel (arlo-cel), a GPRC5D-targeted chimeric antigen receptor (CAR) T cell therapy, in combination with mezigdomide (MEZI) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)

Free
Susan Bal, Luciano Costa, Nizar Bahlis, Myo Htut, Omar Nadeem, Krina Patel, Scott Solomon, Jaclyn Davis, Ziyan Guo, Kevin Hsu, Hongxiang Hu, Krishna R. Juluri, Jessica Katz, Timothy Pulham, Safiyyah Ziyad, Sham Mailankody
Journal: Blood
Blood (2025) 146 (Supplement 1): 5807.
https://doi.org/10.1182/blood-2025-5807
Published: 2025
Journal Articles

Assessment of pharmacodynamic efficacy biomarkers from A phase 1, first-in-human study of arlocabtagene autoleucel (arlo-cel) in relapsed and refractory multiple myeloma (RRMM)

Free
Safiyyah Ziyad, Kristina Jordahl, Hongxiang Hu, Ethan Thompson, Susan Bal, Myo Htut, Larry Anderson, Tara Gregory, Luciano Costa, Omar Nadeem, Naomey Sarkis, Ziyan Guo, Wei-Ming Kao, Allison Kaeding, Shari Kaiser, Michael Burgess, Jesús Berdeja
Journal: Blood
Blood (2025) 146 (Supplement 1): 2223.
https://doi.org/10.1182/blood-2025-2223
Published: 2025
Journal Articles

BMS-986393, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted CAR T Cell Therapy, in Patients (pts) with Relapsed/Refractory (RR) Multiple Myeloma (MM) and 1-3 Prior Regimens: Updated Phase 1 Safety and Efficacy Results

Free
Susan Bal, Myo Htut, Jesús G. Berdeja, Larry D Anderson, Jr., Adriana Rossi, Tara Gregory, Thomas G Martin, Luciano J. Costa, Hongxiang Hu, Jinjie Chen, Chaoqun Mei, Naomey Sarkis, Alok Shrestha, Safiyyah Ziyad, Wei-Ming Kao, Allison J Kaeding, Michael R. Burgess, Omar Nadeem
Journal: Blood
Blood (2024) 144 (Supplement 1): 2069.
https://doi.org/10.1182/blood-2024-203279
Published: 2024
Journal Articles

Efficacy and Safety with Extended Follow-up in a Phase 1 Study of BMS-986393, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted CAR T Cell Therapy, in Patients (pts) with Heavily Pretreated Relapsed/Refractory (RR) Multiple Myeloma (MM)

Free
Susan Bal, Larry D Anderson, Jr., Omar Nadeem, Jesús G. Berdeja, Adriana Rossi, Tara Gregory, Mehmet Hakan Koçoğlu, Thomas G Martin, Daniel N. Egan, Luciano J. Costa, Hongxiang Hu, Jinjie Chen, Chaoqun Mei, Naomey Sarkis, Alok Shrestha, Safiyyah Ziyad, Wei-Ming Kao, Allison J Kaeding, Michael R. Burgess, Myo Htut
Journal: Blood
Blood (2024) 144 (Supplement 1): 922.
https://doi.org/10.1182/blood-2024-201356
Published: 2024
Journal Articles

BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 Study

Free
Susan Bal, Myo Htut, Omar Nadeem, Larry D. Anderson, Jr., Hakan Koçoğlu, Tara Gregory, Adriana C Rossi, Tom Martin, Daniel N. Egan, Luciano Costa, Hongxiang Hu, Yanping Chen, Shaoyi Li, Lisa M. Kelly, Naomey Sarkis, Safiyyah Ziyad, Wei-Ming Kao, Allison June Kaeding, Michael R. Burgess, Jésus G Berdeja
Journal: Blood
Blood (2023) 142 (Supplement 1): 219.
https://doi.org/10.1182/blood-2023-181857
Published: 2023
Journal Articles

Clinical Activity of BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma (MM): First Results from a Phase 1, Multicenter, Open-Label Study

Free
Susan Bal, M. Hakan Kocoglu, Omar Nadeem, Myo Htut, Tara Gregory, Larry D. Anderson, Jr., Luciano J. Costa, Tonia J. Buchholz, Safiyyah Ziyad, Meng Li, Yanping Chen, Allison J. Kaeding, Michael R. Burgess, Kristen Hege, Jesus Berdeja
Journal: Blood
Blood (2022) 140 (Supplement 1): 883–885.
https://doi.org/10.1182/blood-2022-162395
Published: 2022
Journal Articles

JCARH125, Anti-BCMA CAR T-cell Therapy for Relapsed/Refractory Multiple Myeloma: Initial Proof of Concept Results from a Phase 1/2 Multicenter Study (EVOLVE)

Free
Sham Mailankody, MBBS, Myo Htut, MD, Kelvin P. Lee, MD, William Bensinger, MD, Todd Devries, PhD, Julia Piasecki, BA, Safiyyah Ziyad, PhD, Michelle Blake, PhD, John Byon, MDPhD, Andrzej Jakubowiak, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 957.
https://doi.org/10.1182/blood-2018-99-113548
Published: 2018